9-Isopropylazabicyclo<3.3.1>nonan | 64776-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 9-Isopropylazabicyclo<3.3.1>nonan
• 英文别名: N-Isopropylnorpseudopelletierin；9-isopropyl-9-aza-bicyclo[3.3.1]nonane；9-Azabicyclo(3.3.1)nonane, 9-(1-methylethyl)-；9-propan-2-yl-9-azabicyclo[3.3.1]nonane
• CAS: 64776-33-6
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: YFOFKBUFGSOZIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (1R,4Z,8R)-8-(propan-2-ylamino)cyclooct-4-en-1-ol 生成 9-Isopropylazabicyclo<3.3.1>nonan
  参考文献：
  名称：

  BARRELLE M.; APPARU M., TETRAHEDRON, 1977, 33, NO 11, 1309-1319

  摘要：

  DOI：

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170217974A1

  公开（公告）日：2017-08-03

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I）或其药学上可接受的盐、酯或前药： X-A-Y-Z-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Inhibitors of Human Immunodeficiency Virus Replication
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20130231331A1

  公开（公告）日：2013-09-05

  The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及到式I的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。
• HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS
  申请人：AQUINO Christopher Joseph

  公开号：US20090053172A1

  公开（公告）日：2009-02-26

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于治疗CCR5相关的疾病和障碍，例如，用于抑制HIV复制，预防或治疗HIV感染，并用于治疗由此导致的获得性免疫缺陷综合症（AIDS）。
• COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS
  申请人：BIOGEN IDEC MA INC.

  公开号：US20150183741A1

  公开（公告）日：2015-07-02

  Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

  公式(I)的化合物可以调节一个或多个SIP受体的活性和/或自动趋化素(ATX)的活性。
• ATX MODULATING AGENTS
  申请人：BIOGEN IDEC MA INC.

  公开号：US20150210647A1

  公开（公告）日：2015-07-30

  Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

  本发明公开了式（I）的双环芳基化合物，可以调节自体移行素（ATX）酶的活性。本发明还涉及ATX抑制剂化合物以及制备和使用这种化合物治疗因损伤或疾病引起的脱髓鞘和治疗增生性疾病如癌症的方法。